Plasma phosphorylated tau181 outperforms [<scp><sup>18</sup>F</scp>] <scp>fluorodeoxyglucose positron emission tomography</scp> in the identification of early Alzheimer disease
Overall, although both plasma p-tau181 and [<sup>18</sup>F]FDG-PET were associated with core AD biomarkers, plasma p-tau181 outperformed [<sup>18</sup>F]FDG-PET in identifying individuals with early AD pathophysiology. Taken together, our study suggests that plasma p-tau181 may aid in detecting individuals with underlying early AD.
Authors
- Serge Gauthier (ORCID: https://orcid.org/0000-0003-4272-3330)
- Bertrand J. Jean‐Claude (ORCID: https://orcid.org/0000-0002-4312-6485)
- Tharick Ali Pascoal (ORCID: https://orcid.org/0000-0001-9057-8014)
- Joseph Therriault (ORCID: https://orcid.org/0000-0002-7826-4781)
- Nicholas James Ashton (ORCID: https://orcid.org/0000-0002-3579-8804)
- Eduardo Rigon Zimmer (ORCID: https://orcid.org/0000-0002-5349-0053)
- Brian M. Gilfix (ORCID: https://orcid.org/0000-0001-5165-7422)
- Kaj Blennow (ORCID: https://orcid.org/0000-0002-1890-4193)
- Jean‐Paul Soucy (ORCID: https://orcid.org/0000-0001-6979-1259)
- Jaime Fernández Arias (ORCID: https://orcid.org/0000-0002-6810-5920)
- Nesrine Rahmouni (ORCID: https://orcid.org/0009-0004-3081-8468)
- Andréa Lessa Benedet (ORCID: https://orcid.org/0000-0001-8219-1741)
- Arthur C. Macedo (ORCID: https://orcid.org/0000-0002-3957-0284)
- Thomas K. Karikari (ORCID: https://orcid.org/0000-0003-1422-4358)
- Seyyed Ali Hosseini (ORCID: https://orcid.org/0000-0001-7542-7541)
- Stijn Servaes (ORCID: https://orcid.org/0000-0003-3565-1930)
- Takashi Matsudaira (ORCID: https://orcid.org/0000-0002-6602-1301)
- Firoza Zubeida Lussier (ORCID: https://orcid.org/0000-0002-6877-4825)
- Cécile Tissot (ORCID: https://orcid.org/0000-0003-2711-3833)
- Kely Quispialaya (ORCID: https://orcid.org/0009-0000-6982-7143)
- Henrik Zetterberg (ORCID: https://orcid.org/0000-0003-3930-4354)
- Pedro Rosa‐Neto (ORCID: https://orcid.org/0000-0001-9116-1376)
- Yi‐Ting Wang (ORCID: https://orcid.org/0000-0003-2008-4435)
- Jenna Stevenson (ORCID: https://orcid.org/0000-0003-2848-1451)
- Antonio Aliaga (ORCID: https://orcid.org/0009-0006-9792-7815)
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Universidade Federal do Rio Grande do Sul (BR)
- University of Pittsburgh (US)
- Douglas Mental Health University Institute (CA)
- Sahlgrenska University Hospital (SE)
- Hamamatsu University School of Medicine (JP)
- National Epilepsy Center (JP)
- Wallenberg Wood Science Center (SE)
- UK Dementia Research Institute (GB)
- National Hospital Organization (JP)
- University College London (GB)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- McGill University (CA)
- University of Gothenburg (SE)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1111/ene.16255
- Citations
- 7
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.70
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Biogen
- University of Southern California
- F. Hoffmann-La Roche
- Alzheimer's Disease Neuroimaging Initiative
- Familjen Erling-Perssons Stiftelse
- BioClinica
- McGill University
- Fondation Brain Canada
- Northern California Institute for Research and Education
- Stiftelsen för Gamla Tjänarinnor
- Weston Brain Institute
- EU Joint Programme – Neurodegenerative Disease Research
- Consortium canadien en neurodégénérescence associée au vieillissement
- National Institute for Health and Care Research
- University College London
- European Commission
- Eisai
- Hjärnfonden
- Vetenskapsrådet
- UK Dementia Research Institute
- National Institutes of Health
- Genentech
- University of California, San Diego
- HORIZON EUROPE Framework Programme
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé